AGO Recommendations for the Diagnosis and Treatment of Patients with Advanced and Metastatic Breast Cancer: Update 2017

Every year the Breast Committee of the Arbeitsgemeinschaft Gynakologische Onkologie (German Gynecological Oncology Group, AGO), a group of gynecological oncologists specialized in breast cancer and interdisciplinary members specialized in pathology, radiologic diagnostics, medical oncology, and radiation oncology, prepares and updates evidence-based recommendations for the diagnosis and treatment of patients with early and metastatic breast cancer. Every update is performed according to a documented rule-fixed algorithm, by thoroughly reviewing and scoring the recent publications for their scientific validity and clinical relevance. This current publication presents the 2019 update on the recommendations for metastatic breast cancer.

[1]  Anna Lee,et al.  Stimulation of the wrist acupuncture point PC6 for preventing postoperative nausea and vomiting. , 2015, The Cochrane database of systematic reviews.

[2]  Sung-Bae Kim,et al.  Pertuzumab, trastuzumab, and docetaxel in HER2-positive metastatic breast cancer. , 2015, The New England journal of medicine.

[3]  S. Loibl,et al.  Phase III trial evaluating the addition of bevacizumab to endocrine therapy as first-line treatment for advanced breast cancer: the letrozole/fulvestrant and avastin (LEA) study. , 2015, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[4]  G. Luppi,et al.  Brain metastases: an overview. , 2015, CNS oncology.

[5]  K. Michaëlsson,et al.  Risk of atypical femoral fracture during and after bisphosphonate use , 2015, Acta orthopaedica.

[6]  N. Kroman,et al.  Sentinel Lymph Node Dissection in Locally Recurrent Breast Cancer , 2015, Annals of Surgical Oncology.

[7]  A. Vickers,et al.  WITHDRAWN: Acupuncture-point stimulation for chemotherapy-induced nausea or vomiting. , 2014, The Cochrane database of systematic reviews.

[8]  H. Bartelink,et al.  Gene expression profiling to predict the risk of locoregional recurrence in breast cancer: a pooled analysis , 2014, Breast Cancer Research and Treatment.

[9]  D. Doval,et al.  Maintenance capecitabine and bevacizumab versus bevacizumab alone after initial first-line bevacizumab and docetaxel for patients with HER2-negative metastatic breast cancer (IMELDA): a randomised, open-label, phase 3 trial. , 2014, The Lancet. Oncology.

[10]  M. Piccart,et al.  ESO-ESMO 2nd international consensus guidelines for advanced breast cancer (ABC2)† , 2014, Annals of oncology : official journal of the European Society for Medical Oncology.

[11]  W. Gradishar,et al.  Efficacy and safety of continued zoledronic acid every 4 weeks versus every 12 weeks in women with bone metastases from breast cancer: Results of the OPTIMIZE-2 trial. , 2014, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[12]  Sung-Bae Kim,et al.  Trastuzumab emtansine versus treatment of physician's choice for pretreated HER2-positive advanced breast cancer (TH3RESA): a randomised, open-label, phase 3 trial. , 2014, The Lancet. Oncology.

[13]  R. Greil,et al.  Predicting local recurrence using PAM50 in postmenopausal endocrine responsive breast cancer patients. , 2014 .

[14]  A. Goldhirsch,et al.  A meta-analysis of oestrogen receptor, progesterone receptor and human epidermal growth factor receptor 2 discordance between primary breast cancer and metastases. , 2014, European journal of cancer.

[15]  A. McTiernan,et al.  Body mass index and survival in women with breast cancer—systematic literature review and meta-analysis of 82 follow-up studies , 2014, Annals of oncology : official journal of the European Society for Medical Oncology.

[16]  C. Tempany,et al.  Magnetic Resonance–Guided Focused Ultrasound for Patients With Painful Bone Metastases: Phase III Trial Results , 2014, Journal of the National Cancer Institute.

[17]  T. Fehm,et al.  Clinical validity of circulating tumour cells in patients with metastatic breast cancer: a pooled analysis of individual patient data. , 2014, The Lancet. Oncology.

[18]  Yanfen Cui,et al.  The efficacy of bevacizumab plus paclitaxel as first-line treatment for HER2-negative metastatic breast cancer: a meta-analysis of randomized controlled trials , 2014, Tumor Biology.

[19]  R. Gelber,et al.  Chemotherapy for isolated locoregional recurrence of breast cancer (CALOR): a randomised trial. , 2014, The Lancet. Oncology.

[20]  M. Tonato,et al.  Aprepitant versus dexamethasone for preventing chemotherapy-induced delayed emesis in patients with breast cancer: a randomized double-blind study. , 2014, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[21]  Eld,et al.  ESO-ESMO 2nd international consensus guidelines for advanced breast cancer (ABC2) , 2014, Breast.

[22]  I. Zuna,et al.  Final results from the prospective phase III WSG-ARA trial: impact of adjuvant darbepoetin alfa on event-free survival in early breast cancer. , 2014, Annals of oncology : official journal of the European Society for Medical Oncology.

[23]  Marisa C. Jenkins,et al.  Combination versus sequential single agent chemotherapy for metastatic breast cancer. , 2013, The Cochrane database of systematic reviews.

[24]  I. Mittra,et al.  Abstract S2-02: Surgical removal of primary tumor and axillary lymph nodes in women with metastatic breast cancer at first presentation: A randomized controlled trial , 2013 .

[25]  M. Breteler,et al.  Late effects of adjuvant chemotherapy for adult onset non-CNS cancer; cognitive impairment, brain structure and risk of dementia. , 2013, Critical reviews in oncology/hematology.

[26]  S. Paik,et al.  Definitive results of a phase III adjuvant trial comparing three chemotherapy regimens in women with operable, node-positive breast cancer: the NSABP B-38 trial. , 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[27]  A. Schneeweiss,et al.  Adding Epoetin Alfa to Intense Dose-Dense Adjuvant Chemotherapy for Breast Cancer: Randomized Clinical Trial , 2013, Journal of the National Cancer Institute.

[28]  D. Amadori,et al.  Cardiac tolerability of pertuzumab plus trastuzumab plus docetaxel in patients with HER2-positive metastatic breast cancer in CLEOPATRA: a randomized, double-blind, placebo-controlled phase III study. , 2013, The oncologist.

[29]  E. Perez,et al.  Phase II randomized study of trastuzumab emtansine versus trastuzumab plus docetaxel in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer. , 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[30]  S. Aebi,et al.  Chemotherapy Prolongs Survival for Isolated Local or Regional Recurrence of Breast Cancer: The CALOR Trial , 2013 .

[31]  L. Chow,et al.  Randomized phase III placebo-controlled trial of letrozole plus oral temsirolimus as first-line endocrine therapy in postmenopausal women with locally advanced or metastatic breast cancer. , 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[32]  M. Campone,et al.  Lapatinib plus capecitabine in patients with previously untreated brain metastases from HER2-positive metastatic breast cancer (LANDSCAPE): a single-group phase 2 study. , 2013, The Lancet. Oncology.

[33]  S. Bhatia,et al.  The shifting landscape of metastatic breast cancer to the CNS , 2013, Neurosurgical Review.

[34]  S. Zangos,et al.  Thermal ablation therapies in patients with breast cancer liver metastases: A review , 2013, European Radiology.

[35]  A. Naeim,et al.  Pegfilgrastim prophylaxis is associated with a lower risk of hospitalization of cancer patients than filgrastim prophylaxis: a retrospective United States claims analysis of granulocyte colony-stimulating factors (G-CSF) , 2013, BMC Cancer.

[36]  R. Gelber,et al.  Abstract S3-2: Chemotherapy prolongs survival for isolated local or regional recurrence of breast cancer: The CALOR trial (Chemotherapy as Adjuvant for Locally Recurrent breast cancer; IBCSG 27-02, NSABP B-37, BIG 1-02) , 2012 .

[37]  S. Loibl,et al.  Abstract S1-7: Phase III trial evaluating the addition of bevacizumab to endocrine therapy as first-line treatment for advanced breast cancer – First efficacy results from the LEA study. , 2012 .

[38]  A. Leo,et al.  Final analysis of overall survival for the Phase III CONFIRM trial: fulvestrant 500 mg versus 250 mg , 2012 .

[39]  J. Baselga,et al.  Trastuzumab emtansine for HER2-positive advanced breast cancer. , 2012, The New England journal of medicine.

[40]  T. Fehm,et al.  Clinical application of circulating tumor cells in breast cancer: overview of the current interventional trials , 2012, Cancer and Metastasis Reviews.

[41]  M. Gnant,et al.  Ovarian function suppression and fulvestrant as endocrine therapy in premenopausal women with metastatic breast cancer. , 2012, European journal of cancer.

[42]  I. Ray-Coquard,et al.  Randomized phase II trial of everolimus in combination with tamoxifen in patients with hormone receptor-positive, human epidermal growth factor receptor 2-negative metastatic breast cancer with prior exposure to aromatase inhibitors: a GINECO study. , 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[43]  T. Demmy,et al.  Optimal management of malignant pleural effusions (results of CALGB 30102). , 2012, Journal of the National Comprehensive Cancer Network : JNCCN.

[44]  Robert B Livingston,et al.  Combination anastrozole and fulvestrant in metastatic breast cancer. , 2012, The New England journal of medicine.

[45]  Luigi Corti,et al.  The activity and safety of electrochemotherapy in persistent chest wall recurrence from breast cancer after mastectomy: a phase-II study , 2012, Breast Cancer Research and Treatment.

[46]  J. Haerting,et al.  Vascular-endothelial-growth-factor (VEGF) targeting therapies for endocrine refractory or resistant metastatic breast cancer. , 2012, The Cochrane database of systematic reviews.

[47]  J. Gehl,et al.  Electrochemotherapy for large cutaneous recurrence of breast cancer: A phase II clinical trial , 2012, Acta oncologica.

[48]  Dirk Rades,et al.  Radiotherapeutic and surgical management for newly diagnosed brain metastasis(es): An American Society for Radiation Oncology evidence-based guideline , 2012, Practical radiation oncology.

[49]  F. Strasser.  Faculty Opinions recommendation of American Society of Clinical Oncology provisional clinical opinion: the integration of palliative care into standard oncology care. , 2012 .

[50]  J. Bergh,et al.  Clinically used breast cancer markers such as estrogen receptor, progesterone receptor, and human epidermal growth factor receptor 2 are unstable throughout tumor progression. , 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[51]  K. Takabe,et al.  The evolution of the role of surgery in the management of breast cancer lung metastasis. , 2012, Journal of thoracic disease.

[52]  J. Bergh,et al.  FACT: an open-label randomized phase III study of fulvestrant and anastrozole in combination compared with anastrozole alone as first-line therapy for patients with receptor-positive postmenopausal breast cancer. , 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[53]  C. Hudis,et al.  1st International consensus guidelines for advanced breast cancer (ABC 1). , 2012, Breast.

[54]  S. Loibl,et al.  Everolimus (RAD) as treatment in breast cancer patients with bone metastases only: Results of the phase II RADAR study. , 2012 .

[55]  H. Kuerer,et al.  Resection of liver metastases from breast cancer: estrogen receptor status and response to chemotherapy before metastasectomy define outcome. , 2012, Surgery.

[56]  E. Rakovitch,et al.  Whole brain radiotherapy for the treatment of newly diagnosed multiple brain metastases. , 2012, The Cochrane database of systematic reviews.

[57]  P. Brown,et al.  Effect of tumor subtype on survival and the graded prognostic assessment for patients with breast cancer and brain metastases. , 2012, International journal of radiation oncology, biology, physics.

[58]  Amy P Abernethy,et al.  American Society of Clinical Oncology provisional clinical opinion: the integration of palliative care into standard oncology care. , 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[59]  Jun Liu,et al.  Loss of human epidermal growth factor receptor 2 (HER2) expression in metastatic sites of HER2-overexpressing primary breast tumors. , 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[60]  Mark Clemons,et al.  Prospective study evaluating the impact of tissue confirmation of metastatic disease in patients with breast cancer. , 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[61]  R. Gelber,et al.  Lapatinib with trastuzumab for HER2-positive early breast cancer (NeoALTTO): a randomised, open-label, multicentre, phase 3 trial , 2012, The Lancet.

[62]  Xianghua Luo,et al.  Summary report on the graded prognostic assessment: an accurate and facile diagnosis-specific tool to estimate survival for patients with brain metastases. , 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[63]  Sung-Bae Kim,et al.  Pertuzumab plus trastuzumab plus docetaxel for metastatic breast cancer. , 2012, The New England journal of medicine.

[64]  J. Thigpen.  Everolimus in Postmenopausal Hormone-Receptor–Positive Advanced Breast Cancer , 2012 .

[65]  M. Kerin,et al.  Locoregional recurrence after breast cancer surgery: a systematic review by receptor phenotype , 2012, Breast Cancer Research and Treatment.

[66]  M. Baum,et al.  Long-term results of targeted intraoperative radiotherapy (Targit) boost during breast-conserving surgery. , 2011, International journal of radiation oncology, biology, physics.

[67]  T. Fehm,et al.  Symptomatic bone marrow involvement in breast cancer--clinical presentation, treatment, and prognosis: a single institution review of 22 cases. , 2011, Anticancer research.

[68]  T. Colgan,et al.  The evolving role of axillary lymph node fine‐needle aspiration in the management of carcinoma of the breast , 2011, Cancer cytopathology.

[69]  W. Woodward,et al.  Long-term outcomes in patients with isolated supraclavicular nodal recurrence after mastectomy and doxorubicin-based chemotherapy for breast cancer. , 2011, International journal of radiation oncology, biology, physics.

[70]  S. Ciatto,et al.  Preoperative Ultrasound-Guided Needle Biopsy of Axillary Nodes in Invasive Breast Cancer: Meta-Analysis of Its Accuracy and Utility in Staging the Axilla , 2011, Annals of surgery.

[71]  M. Héry,et al.  Radiotherapy for invasive breast cancer: guidelines for clinical practice from the French expert review board of Nice/Saint-Paul de Vence. , 2011, Critical reviews in oncology/hematology.

[72]  H. Wildiers,et al.  EORTC workshop on clinical trial methodology in older individuals with a diagnosis of solid tumors. , 2011, Annals of oncology : official journal of the European Society for Medical Oncology.

[73]  A. Tremblay,et al.  Pleural controversy: Pleurodesis versus indwelling pleural catheters for malignant effusions , 2011, Respirology.

[74]  S. Payne,et al.  What is the evidence for the use of mindfulness‐based interventions in cancer care? A review , 2011, Psycho-oncology.

[75]  R. Gelber,et al.  Strategies for subtypes—dealing with the diversity of breast cancer: highlights of the St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2011 , 2011, Annals of oncology : official journal of the European Society for Medical Oncology.

[76]  H. Dickinson,et al.  Cardioprotective interventions for cancer patients receiving anthracyclines. , 2011, The Cochrane database of systematic reviews.

[77]  M. Morrow,et al.  Clinical management factors contribute to the decision for contralateral prophylactic mastectomy. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[78]  P. Rosenberg,et al.  Declining incidence of contralateral breast cancer in the United States from 1975 to 2006. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[79]  O. Olopade,et al.  Predictors of contralateral breast cancer in BRCA1 and BRCA2 mutation carriers , 2011, British Journal of Cancer.

[80]  M. Ernst,et al.  Meta-analysis of predictive factors for non-sentinel lymph node metastases in breast cancer patients with a positive SLN. , 2011, European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology.

[81]  P. Francis,et al.  Tamoxifen, cytochrome P450 genes and breast cancer clinical outcomes. , 2011, Breast.

[82]  A. Luini,et al.  Prognosis in women with small (T1mic,T1a,T1b) node-negative operable breast cancer by immunohistochemically selected subtypes , 2011, Breast Cancer Research and Treatment.

[83]  E. Lund,et al.  Vitamin D‐effective solar UV radiation, dietary vitamin D and breast cancer risk , 2011, International journal of cancer.

[84]  A. Giuliano,et al.  Axillary dissection vs no axillary dissection in women with invasive breast cancer and sentinel node metastasis: a randomized clinical trial. , 2011, JAMA.

[85]  M. Toulmonde,et al.  A review of PARP inhibitors: from bench to bedside. , 2011, Annals of oncology : official journal of the European Society for Medical Oncology.

[86]  V. Beral,et al.  Breast Cancer Risk in Relation to the Interval Between Menopause and Starting Hormone Therapy , 2011, Journal of the National Cancer Institute.

[87]  Mark Yoffe,et al.  Iniparib plus chemotherapy in metastatic triple-negative breast cancer. , 2011, The New England journal of medicine.

[88]  J. Yarnold,et al.  Hypofractionated whole-breast radiotherapy for women with early breast cancer: myths and realities. , 2011, International journal of radiation oncology, biology, physics.

[89]  M. Rela,et al.  Resection of liver metastases from breast cancer: towards a management guideline. , 2011, International journal of surgery.

[90]  Wendy B DeMartini,et al.  Atypical ductal hyperplasia on vacuum-assisted breast biopsy: suspicion for ductal carcinoma in situ can stratify patients at high risk for upgrade. , 2011, Human pathology.

[91]  M. Ewertz,et al.  Effect of obesity on prognosis after early-stage breast cancer. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[92]  J. Chang-Claude,et al.  Menopausal hormone therapy and breast cancer risk: Impact of different treatments. The European Prospective Investigation into Cancer and Nutrition , 2011, International journal of cancer.

[93]  Dawn L. Hershman,et al.  Early discontinuation and non-adherence to adjuvant hormonal therapy are associated with increased mortality in women with breast cancer , 2011, Breast Cancer Research and Treatment.

[94]  N. Sneige,et al.  Atypical Ductal Hyperplasia in Directional Vacuum-Assisted Biopsy of Breast Microcalcifications: Considerations for Surgical Excision , 2011, Annals of Surgical Oncology.

[95]  Y. Fujiwara,et al.  Denosumab compared with zoledronic acid for the treatment of bone metastases in patients with advanced breast cancer: a randomized, double-blind study. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[96]  A. Ruíz,et al.  Adjuvant docetaxel for high-risk, node-negative breast cancer. , 2010, The New England journal of medicine.

[97]  Jorge S Reis-Filho,et al.  Triple-negative breast cancer. , 2010, The New England journal of medicine.

[98]  A. Thompson,et al.  Prospective comparison of switches in biomarker status between primary and recurrent breast cancer: the Breast Recurrence In Tissues Study (BRITS) , 2010, Breast Cancer Research.

[99]  S. Rizzo,et al.  Stereotactic vacuum-assisted breast biopsy is not a therapeutic procedure even when all mammographically found calcifications are removed: analysis of 4,086 procedures. , 2010, AJR. American journal of roentgenology.

[100]  S. Cozzi,et al.  Management of Neoplastic Pericardial Effusions , 2010, Tumori.

[101]  E. Petru,et al.  Proteolytische Enzymtherapie mit Wobe Mugos® gegen Chemotherapie-bedingte Toxizitäten bei Brustkrebs-Patientinnen – Ergebnisse einer Pilotstudie , 2010, Wiener Medizinische Wochenschrift.

[102]  P. Neven,et al.  Efficacy of zoledronic acid in postmenopausal women with early breast cancer receiving adjuvant letrozole: 36-month results of the ZO-FAST Study. , 2010, Annals of oncology : official journal of the European Society for Medical Oncology.

[103]  M. Lichinitser,et al.  Results of the CONFIRM phase III trial comparing fulvestrant 250 mg with fulvestrant 500 mg in postmenopausal women with estrogen receptor-positive advanced breast cancer. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[104]  J. Manson,et al.  Estrogen plus progestin and breast cancer incidence and mortality in postmenopausal women. , 2010, JAMA.

[105]  Christian M Langton,et al.  Accelerated Partial Breast Irradiation (APBI): A review of available techniques , 2010, Radiation oncology.

[106]  Christiana Kartsonaki,et al.  A locus on 19p13 modifies risk of breast cancer in BRCA1 mutation carriers and is associated with hormone receptor–negative breast cancer in the general population , 2010, Nature Genetics.

[107]  Matthew Freiberg,et al.  Alcohol consumption and risk of postmenopausal breast cancer by subtype: the women's health initiative observational study. , 2010, Journal of the National Cancer Institute.

[108]  R. Elashoff,et al.  Differential response of triple‐negative breast cancer to a docetaxel and carboplatin‐based neoadjuvant treatment , 2010, Cancer.

[109]  A. Trichopoulou,et al.  Conformity to traditional Mediterranean diet and breast cancer risk in the Greek EPIC (European Prospective Investigation into Cancer and Nutrition) cohort. , 2010, The American journal of clinical nutrition.

[110]  Kelly K. Hunt,et al.  Locoregional recurrence after sentinel lymph node dissection with or without axillary dissection in patients with sentinel lymph node metastases: the American College of Surgeons Oncology Group Z0011 randomized trial. , 2010, Annals of surgery.

[111]  Elio Riboli,et al.  Diet and cancer prevention: Contributions from the European Prospective Investigation into Cancer and Nutrition (EPIC) study. , 2010, European journal of cancer.

[112]  Rosalind Eeles,et al.  Association of risk-reducing surgery in BRCA1 or BRCA2 mutation carriers with cancer risk and mortality. , 2010, JAMA.

[113]  C. la Vecchia,et al.  Hormonal contraception and risk of cancer. , 2010, Human reproduction update.

[114]  A. Luini,et al.  Intraoperative radiotherapy during breast conserving surgery: a study on 1,822 cases treated with electrons , 2010, Breast Cancer Research and Treatment.

[115]  C. Loprinzi,et al.  International Journal of Women's Health Dovepress Management of Menopause-associated Vasomotor Symptoms: Current Treatment Options, Challenges and Future Directions , 2022 .

[116]  J. Manson,et al.  Oral bisphosphonate use and breast cancer incidence in postmenopausal women. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[117]  A. Tutt,et al.  Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and recurrent ovarian cancer: a proof-of-concept trial , 2010, The Lancet.

[118]  P. Dobkin,et al.  Weathering storms: a cohort study of how participation in a mindfulness-based stress reduction program benefits women after breast cancer treatment. , 2010, Current oncology.

[119]  P. Goodwin,et al.  Obesity and hormone therapy in breast cancer: an unfinished puzzle. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[120]  J. Cuzick,et al.  Effect of body mass index on recurrences in tamoxifen and anastrozole treated women: an exploratory analysis from the ATAC trial. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[121]  P. Neven,et al.  Results of a phase II study comparing three dosing regimens of fulvestrant in postmenopausal women with advanced breast cancer (FINDER2) , 2010, Breast Cancer Research and Treatment.

[122]  Arlene Chan,et al.  Phase III study of bevacizumab plus docetaxel compared with placebo plus docetaxel for the first-line treatment of human epidermal growth factor receptor 2-negative metastatic breast cancer. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[123]  L. Esserman,et al.  Targeted intraoperative radiotherapy versus whole breast radiotherapy for breast cancer (TARGIT-A trial): an international, prospective, randomised, non-inferiority phase 3 trial , 2010, The Lancet.

[124]  L. Schapira,et al.  Ovarian reserve in women who remain premenopausal after chemotherapy for early stage breast cancer. , 2010, Fertility and sterility.

[125]  P. Alfonso,et al.  Phase II study of neoadjuvant treatment with doxorubicin, docetaxel, and capecitabine (ATX) in locally advanced or inflammatory breast cancer , 2010, Breast cancer.

[126]  L. V. van de Poll-Franse,et al.  Staging and management of axillary lymph nodes in patients with local recurrence in the breast or chest wall after a previous negative sentinel node procedure. , 2010, European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology.

[127]  A. Makris,et al.  DNA repair signature is associated with anthracycline response in triple negative breast cancer patients , 2010, Breast Cancer Research and Treatment.

[128]  K. Courneya,et al.  Exercise interventions for upper-limb dysfunction due to breast cancer treatment. , 2010, The Cochrane database of systematic reviews.

[129]  Andreas Schneeweiss,et al.  Intense dose-dense sequential chemotherapy with epirubicin, paclitaxel, and cyclophosphamide compared with conventionally scheduled chemotherapy in high-risk primary breast cancer: mature results of an AGO phase III study. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[130]  I. Olivotto,et al.  Hypofractionation should be the new 'standard' for radiation therapy after breast conserving surgery. , 2010, Breast.

[131]  Anthony Rhodes,et al.  American Society of Clinical Oncology/College of American Pathologists guideline recommendations for immunohistochemical testing of estrogen and progesterone receptors in breast cancer. , 2010, Archives of pathology & laboratory medicine.

[132]  Suzanne F. Jones,et al.  Phase I study of trastuzumab-DM1, an HER2 antibody-drug conjugate, given every 3 weeks to patients with HER2-positive metastatic breast cancer. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[133]  R. Weinshilboum,et al.  Coprescription of tamoxifen and medications that inhibit CYP2D6. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[134]  B. Hickey,et al.  The less than whole breast radiotherapy approach. , 2010, Breast.

[135]  A. Rodger.  Should fewer fractions be the new standard for postoperative radiotherapy in patients with early breast cancer? , 2010, Breast.

[136]  A phase II trial of capecitabine and docetaxel followed by 5-fluorouracil/epirubicin/cyclophosphamide (FEC) as preoperative treatment in women with stage II/III breast cancer. , 2010, Annals of oncology : official journal of the European Society for Medical Oncology.

[137]  L. Tafra,et al.  American Society of Clinical Oncology‐recommended surveillance and physician specialty among long‐term breast cancer survivors , 2010, Cancer.

[138]  S. Brennan,et al.  Dietary patterns and breast cancer risk: a systematic review and meta-analysis. , 2010, The American journal of clinical nutrition.

[139]  Ultrasound of the axilla: where to look for the sentinel lymph node. , 2010, Clinical radiology.

[140]  D. Mavroudis,et al.  Partial Breast Irradiation or Whole Breast Radiotherapy for Early Breast Cancer: A Meta‐Analysis of Randomized Controlled Trials , 2010, The breast journal.

[141]  Dieter Niederacher,et al.  Germline mutations in breast and ovarian cancer pedigrees establish RAD51C as a human cancer susceptibility gene , 2010, Nature Genetics.

[142]  Peter A Fasching,et al.  Neoadjuvant treatment with trastuzumab in HER2-positive breast cancer: results from the GeparQuattro study. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[143]  K. Tatsch,et al.  Radiofrequency ablation after selective internal radiation therapy with Yttrium90 microspheres in metastatic liver disease-Is it feasible? , 2010, European journal of radiology.

[144]  Anthony Fyles,et al.  Long-term results of hypofractionated radiation therapy for breast cancer. , 2010, The New England journal of medicine.

[145]  J. Baselga,et al.  Open-label, phase II, multicenter, randomized study of the efficacy and safety of two dose levels of Pertuzumab, a human epidermal growth factor receptor 2 dimerization inhibitor, in patients with human epidermal growth factor receptor 2-negative metastatic breast cancer. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[146]  J. Baselga,et al.  Randomized study of Lapatinib alone or in combination with trastuzumab in women with ErbB2-positive, trastuzumab-refractory metastatic breast cancer. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[147]  M. Bollet,et al.  Simultaneous integrated boost in breast conserving treatment of breast cancer: a dosimetric comparison of helical tomotherapy and three-dimensional conformal radiotherapy. , 2010, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.

[148]  R. Pötter,et al.  Patient selection for accelerated partial-breast irradiation (APBI) after breast-conserving surgery: recommendations of the Groupe Européen de Curiethérapie-European Society for Therapeutic Radiology and Oncology (GEC-ESTRO) breast cancer working group based on clinical evidence (2009). , 2010, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.

[149]  K. Gelmon,et al.  Phase II trial of pertuzumab and trastuzumab in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer that progressed during prior trastuzumab therapy. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[150]  X. Shu,et al.  Exercise, tea consumption, and depression among breast cancer survivors. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[151]  S. Willich,et al.  Interaction of serotonin reuptake inhibitors with tamoxifen , 2010, BMJ : British Medical Journal.

[152]  Peter C Austin,et al.  Selective serotonin reuptake inhibitors and breast cancer mortality in women receiving tamoxifen: a population based cohort study , 2010, BMJ : British Medical Journal.

[153]  S. Cremers,et al.  Prevention of bone loss by zoledronic acid in premenopausal women undergoing adjuvant chemotherapy persist up to one year following discontinuing treatment. , 2010, The Journal of clinical endocrinology and metabolism.

[154]  A. DeMichele,et al.  Antimullerian hormone and inhibin B are hormone measures of ovarian function in late reproductive‐aged breast cancer survivors , 2010, Cancer.

[155]  J. Baselga,et al.  Neoadjuvant chemotherapy with trastuzumab followed by adjuvant trastuzumab versus neoadjuvant chemotherapy alone, in patients with HER2-positive locally advanced breast cancer (the NOAH trial): a randomised controlled superiority trial with a parallel HER2-negative cohort , 2010, The Lancet.

[156]  J. Lubiński,et al.  Pathologic complete response rates in young women with BRCA1-positive breast cancers after neoadjuvant chemotherapy. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[157]  U. Albert,et al.  Assessment of fracture risk in women with breast cancer using current vs emerging guidelines , 2010, British Journal of Cancer.

[158]  R. Holloway,et al.  Treatment of malignant pleural effusion: PleuRx catheter or talc pleurodesis? A cost-effectiveness analysis. , 2010, Journal of palliative medicine.

[159]  J. Berlin,et al.  Erythropoiesis-stimulating agents in oncology: a study-level meta-analysis of survival and other safety outcomes , 2010, British Journal of Cancer.

[160]  E. D. Geijsen,et al.  Elective re-irradiation and hyperthermia following resection of persistent locoregional recurrent breast cancer: A retrospective study , 2010, International journal of hyperthermia : the official journal of European Society for Hyperthermic Oncology, North American Hyperthermia Group.

[161]  D. Koukouras,et al.  Is sentinel node biopsy reliable in large breast tumors? , 2010, European journal of gynaecological oncology.

[162]  Carsten Denkert,et al.  Tumor-associated lymphocytes as an independent predictor of response to neoadjuvant chemotherapy in breast cancer. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[163]  E. Perez,et al.  Cyclophosphamide, epirubicin, and Fluorouracil versus dose-dense epirubicin and cyclophosphamide followed by Paclitaxel versus Doxorubicin and cyclophosphamide followed by Paclitaxel in node-positive or high-risk node-negative breast cancer. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[164]  M. Piccart-Gebhart,et al.  Taxanes: optimizing adjuvant chemotherapy for early-stage breast cancer , 2010, Nature Reviews Clinical Oncology.

[165]  P. Fasching,et al.  Impact of treatment characteristics on response of different breast cancer phenotypes: pooled analysis of the German neo-adjuvant chemotherapy trials , 2010, Breast Cancer Research and Treatment.

[166]  W. Ju,et al.  Effects of antioxidant supplements on cancer prevention: meta-analysis of randomized controlled trials. , 2010, Annals of oncology : official journal of the European Society for Medical Oncology.

[167]  J. Sloan,et al.  Pilot study of Panax quinquefolius (American ginseng) to improve cancer-related fatigue: a randomized, double-blind, dose-finding evaluation: NCCTG trial N03CA , 2010, Supportive Care in Cancer.

[168]  U. Bick,et al.  Contralateral breast cancer risk in BRCA1 and BRCA2 mutation carriers. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[169]  J. Lynch,et al.  One-year outcomes of a behavioral therapy intervention trial on sleep quality and cancer-related fatigue. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[170]  V. Kataja,et al.  Adjuvant capecitabine in combination with docetaxel and cyclophosphamide plus epirubicin for breast cancer: an open-label, randomised controlled trial. , 2009, The Lancet. Oncology.

[171]  Funda Meric-Bernstam,et al.  High risk of recurrence for patients with breast cancer who have human epidermal growth factor receptor 2-positive, node-negative tumors 1 cm or smaller. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[172]  J. Mackey,et al.  Trastuzumab plus anastrozole versus anastrozole alone for the treatment of postmenopausal women with human epidermal growth factor receptor 2-positive, hormone receptor-positive metastatic breast cancer: results from the randomized phase III TAnDEM study. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[173]  F. Clavel-Chapelon,et al.  American Journal of Epidemiology Original Contribution Postmenopausal Breast Cancer Risk and Dietary Patterns in the E3n-epic Prospective Cohort Study , 2022 .

[174]  A. Ravi,et al.  Oral contraceptives and family history of breast cancer. , 2009, Contraception.

[175]  M. Ellis,et al.  Activity of fulvestrant 500 mg versus anastrozole 1 mg as first-line treatment for advanced breast cancer: results from the FIRST study. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[176]  S. Shapiro.  Re: "a case-control study of oral contraceptive use and incident breast cancer". , 2009, American journal of epidemiology.

[177]  A. Evans,et al.  CT staging of loco-regional breast cancer recurrence. A worthwhile practice? , 2009, Clinical radiology.

[178]  R. Souchon,et al.  DEGRO Practice Guidelines for Palliative Radiotherapy of Metastatic Breast Cancer , 2009, Strahlentherapie und Onkologie.

[179]  A. Tutt,et al.  Platinum sensitivity in a BRCA1 mutation carrier with advanced breast cancer. , 2009, Clinical oncology (Royal College of Radiologists (Great Britain)).

[180]  M. Schmidt,et al.  Catumaxomab: a bispecific trifunctional antibody. , 2009, Drugs of Today.

[181]  K. Gelmon,et al.  A phase II trial of a neoadjuvant platinum regimen for locally advanced breast cancer: pathologic response, long-term follow-up, and correlation with biomarkers. , 2009, Clinical breast cancer.

[182]  R. Gelber,et al.  Thresholds for therapies: highlights of the St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2009 , 2009, Annals of oncology : official journal of the European Society for Medical Oncology.

[183]  N. Ferrara.  Vascular Endothelial Growth Factor , 2009, Arteriosclerosis, thrombosis, and vascular biology.

[184]  R. Greil,et al.  Endocrine therapy plus zoledronic acid in premenopausal breast cancer. , 2009, The New England journal of medicine.

[185]  M. Tonelli,et al.  Benefits and harms of erythropoiesis-stimulating agents for anemia related to cancer: a meta-analysis , 2009, Canadian Medical Association Journal.

[186]  I. Ellis,et al.  Sequential docetaxel as adjuvant chemotherapy for early breast cancer (TACT): an open-label, phase III, randomised controlled trial , 2009, The Lancet.

[187]  X. Shu,et al.  Use of oral contraceptives, intrauterine devices and tubal sterilization and cancer risk in a large prospective study, from 1996 to 2006 , 2009, International journal of cancer.

[188]  C. Pukall,et al.  An evidence‐based review of yoga as a complementary intervention for patients with cancer , 2009, Psycho-oncology.

[189]  P. Tassone,et al.  Loss of BRCA1 function increases the antitumor activity of cisplatin against human breast cancer xenografts in vivo , 2009, Cancer biology & therapy.

[190]  R. Chlebowski,et al.  Effect of denosumab on bone mineral density in women receiving adjuvant aromatase inhibitors for non-metastatic breast cancer: subgroup analyses of a phase 3 study , 2009, Breast Cancer Research and Treatment.

[191]  Karla Kerlikowske,et al.  Prevention of breast cancer in postmenopausal women: approaches to estimating and reducing risk. , 2009, Journal of the National Cancer Institute.

[192]  A. Hackshaw,et al.  Long-term Effectiveness of Adjuvant Goserelin in Premenopausal Women With Early Breast Cancer , 2009, Journal of the National Cancer Institute.

[193]  G. Constantine,et al.  Desvenlafaxine for the treatment of vasomotor symptoms associated with menopause: a double-blind, randomized, placebo-controlled trial of efficacy and safety. , 2009, American journal of obstetrics and gynecology.

[194]  M. Aapro,et al.  Febrile neutropenia and related complications in breast cancer patients receiving pegfilgrastim primary prophylaxis versus current practice neutropaenia management: results from an integrated analysis. , 2009, European journal of cancer.

[195]  G. Soma,et al.  High-dose vitamin C (ascorbic acid) therapy in the treatment of patients with advanced cancer. , 2009, Anticancer research.

[196]  V. Seewaldt,et al.  Yoga of Awareness program for menopausal symptoms in breast cancer survivors: results from a randomized trial , 2009, Supportive Care in Cancer.

[197]  H. Nagendra,et al.  Effects of a Yoga Program on Cortisol Rhythm and Mood States in Early Breast Cancer Patients Undergoing Adjuvant Radiotherapy: A Randomized Controlled Trial , 2009, Integrative cancer therapies.

[198]  M. Birkhäuser,et al.  Erhöht die hormonale Kontrazeption das Tumorrisiko , 2009 .

[199]  J. Palmer,et al.  American Journal of Epidemiology Original Contribution a Case-control Study of Oral Contraceptive Use and Incident Breast Cancer , 2022 .

[200]  G. Babiera,et al.  Surgical Resection of the Primary Tumor is Associated with Increased Long-Term Survival in Patients with Stage IV Breast Cancer after Controlling for Site of Metastasis , 2009 .

[201]  J. Overgaard,et al.  Accelerated partial breast irradiation as part of breast conserving therapy of early breast carcinoma: a systematic review. , 2009, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.

[202]  J. Jacobson,et al.  Use of antioxidant supplements during breast cancer treatment: a comprehensive review , 2009, Breast Cancer Research and Treatment.

[203]  H. Boezen,et al.  Venlafaxine versus clonidine for the treatment of hot flashes in breast cancer patients: a double-blind, randomized cross-over study , 2009, Breast Cancer Research and Treatment.

[204]  J. Kładny,et al.  Response to neoadjuvant therapy with cisplatin in BRCA1-positive breast cancer patients , 2009, Breast Cancer Research and Treatment.

[205]  A. Hofman,et al.  The CYP2D6*4 polymorphism affects breast cancer survival in tamoxifen users , 2009, Breast Cancer Research and Treatment.

[206]  A. Giobbie-Hurder,et al.  Prognostic and predictive value of centrally reviewed Ki-67 labeling index in postmenopausal women with endocrine-responsive breast cancer: results from Breast International Group Trial 1-98 comparing adjuvant tamoxifen with letrozole. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[207]  T. Keith,et al.  Randomized trial of a hypnosis intervention for treatment of hot flashes among breast cancer survivors. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[208]  D. Scheinberg,et al.  Vitamin C antagonizes the cytotoxic effects of antineoplastic drugs. , 2005, Cancer research.

[209]  R. Durazo-Arvizu,et al.  Effect of mindfulness based stress reduction on immune function, quality of life and coping in women newly diagnosed with early stage breast cancer , 2008, Brain, Behavior, and Immunity.

[210]  H. Earl,et al.  tAnGo: a randomised phase III trial of gemcitabine in paclitaxel-containing, epirubicin/cyclophosphamide-based, adjuvant chemotherapy for early breast cancer: a prospective pulmonary, cardiac and hepatic function evaluation , 2008, British Journal of Cancer.

[211]  M. Jeffery,et al.  Fraction size in radiation treatment for breast conservation in early breast cancer. , 2008, The Cochrane database of systematic reviews.

[212]  B. Strom,et al.  Breast Cancer Risk and Hormone Receptor Status in Older Women by Parity, Age of First Birth, and Breastfeeding: A Case-Control Study , 2008, Cancer Epidemiology Biomarkers & Prevention.

[213]  D. Monti,et al.  Potential role of mind‐body therapies in cancer survivorship , 2008, Cancer.

[214]  R. Gelber,et al.  Estimating the magnitude of trastuzumab effects within patient subgroups in the HERA trial. , 2008, Annals of oncology : official journal of the European Society for Medical Oncology.

[215]  C. Friedenreich,et al.  Physical activity and breast cancer risk: impact of timing, type and dose of activity and population subgroup effects , 2008, British Journal of Sports Medicine.

[216]  S. Hilsenbeck,et al.  Association of Surgery With Improved Survival in Stage IV Breast Cancer Patients , 2008, Annals of surgery.

[217]  Manon Auger,et al.  Accuracy of fine‐needle aspiration cytology of axillary lymph nodes in breast cancer patients , 2008, Cancer.

[218]  A. D. Van den Abbeele,et al.  Phase II trial of lapatinib for brain metastases in patients with human epidermal growth factor receptor 2-positive breast cancer. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[219]  E. Perez,et al.  Weekly paclitaxel in the adjuvant treatment of breast cancer. , 2008, The New England journal of medicine.

[220]  S. Loibl,et al.  Neoadjuvant vinorelbine-capecitabine versus docetaxel-doxorubicin-cyclophosphamide in early nonresponsive breast cancer: phase III randomized GeparTrio trial. , 2008, Journal of the National Cancer Institute.

[221]  J. Haviland,et al.  A randomized controlled trial of relaxation training to reduce hot flashes in women with primary breast cancer. , 2008, Journal of pain and symptom management.

[222]  R. Pazdur,et al.  Dexrazoxane (Totect): FDA review and approval for the treatment of accidental extravasation following intravenous anthracycline chemotherapy. , 2008, The oncologist.

[223]  J R Yarnold,et al.  The UK Standardisation of Breast Radiotherapy (START) Trial B of radiotherapy hypofractionation for treatment of early breast cancer: a randomised trial , 2008, The Lancet.

[224]  W. Warren,et al.  Management of malignant pleural effusions using the Pleur(x) catheter. , 2008, The Annals of thoracic surgery.

[225]  J. Bower.  Behavioral symptoms in patients with breast cancer and survivors. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[226]  G. Constantine,et al.  Efficacy and Tolerability of Desvenlafaxine Succinate Treatment for Menopausal Vasomotor Symptoms: A Randomized Controlled Trial , 2008, Obstetrics and gynecology.

[227]  A. Wolk,et al.  Alcohol intake and risk of breast cancer defined by estrogen and progesterone receptor status—A meta‐analysis of epidemiological studies , 2007, International journal of cancer.

[228]  S. Aranda,et al.  Psychoeducational interventions to alleviate hot flashes: a systematic review , 2007, Menopause.

[229]  C. Criscitiello,et al.  Taxane-based combinations as adjuvant chemotherapy of early breast cancer: a meta-analysis of randomized trials. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[230]  P. Kristjansen,et al.  Effect of radiation therapy on small-cell lung cancer is reduced by ubiquinone intake , 2008, Folia Microbiologica.

[231]  L. Gibson,et al.  Aromatase inhibitors for treatment of advanced breast cancer in postmenopausal women. , 2007, The Cochrane database of systematic reviews.

[232]  M. Casey,et al.  A phase III randomized comparison of lapatinib plus capecitabine versus capecitabine alone in women with advanced breast cancer that has progressed on trastuzumab: updated efficacy and biomarker analyses , 2008, Breast Cancer Research and Treatment.

[233]  E. Perez,et al.  Paclitaxel plus bevacizumab versus paclitaxel alone for metastatic breast cancer. , 2007, The New England journal of medicine.

[234]  R. Bast,et al.  American Society of Clinical Oncology 2007 update of recommendations for the use of tumor markers in breast cancer. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[235]  P. Tartter,et al.  Reoperative sentinel lymph node biopsy in patients with locally recurrent breast cancer. , 2007, American journal of surgery.

[236]  Amanda J Lee,et al.  Cancer risk among users of oral contraceptives: cohort data from the Royal College of General Practitioner's oral contraception study , 2007, BMJ : British Medical Journal.

[237]  Michael W Kattan,et al.  Doctor, what are my chances of having a positive sentinel node? A validated nomogram for risk estimation. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[238]  A. Saykin,et al.  Cognitive‐behavioral management of chemotherapy‐related cognitive change , 2007, Psycho-oncology.

[239]  Lester L. Peters,et al.  Genome-wide association study identifies novel breast cancer susceptibility loci , 2007, Nature.

[240]  D. Jeffe,et al.  Surgical Removal of the Primary Tumor Increases Overall Survival in Patients With Metastatic Breast Cancer: Analysis of the 1988–2003 SEER Data , 2007, Annals of Surgical Oncology.

[241]  L. Leventhal,et al.  Alleviation of thermoregulatory dysfunction with the new serotonin and norepinephrine reuptake inhibitor desvenlafaxine succinate in ovariectomized rodent models. , 2007, Endocrinology.

[242]  S. Loibl,et al.  Venlafaxine is superior to clonidine as treatment of hot flashes in breast cancer patients--a double-blind, randomized study. , 2006, Annals of oncology : official journal of the European Society for Medical Oncology.

[243]  Anthony Rhodes,et al.  American Society of Clinical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer. , 2006, Archives of pathology & laboratory medicine.

[244]  R. Nahta,et al.  HER2 therapy: Molecular mechanisms of trastuzumab resistance , 2006, Breast Cancer Research.

[245]  K. Streitberger,et al.  Acupuncture for nausea and vomiting: An update of clinical and experimental studies , 2006, Autonomic Neuroscience.

[246]  Francesmary Modugno,et al.  Oral contraceptive use as a risk factor for premenopausal breast cancer: a meta-analysis. , 2006, Mayo Clinic proceedings.

[247]  Alan R. Boobis,et al.  Meta-analysis of Studies of Alcohol and Breast Cancer with Consideration of the Methodological Issues , 2006, Cancer Causes & Control.

[248]  G. Dennert,et al.  Selenium for alleviating the side effects of chemotherapy, radiotherapy and surgery in cancer patients. , 2006, The Cochrane database of systematic reviews.

[249]  M. Pike,et al.  Reproductive factors and breast cancer risk according to joint estrogen and progesterone receptor status: a meta-analysis of epidemiological studies , 2006, Breast Cancer Research.

[250]  K. Courneya,et al.  Effects of exercise on breast cancer patients and survivors: a systematic review and meta-analysis , 2006, Canadian Medical Association Journal.

[251]  M. Vessey,et al.  Oral contraceptive use and cancer. Findings in a large cohort study, 1968–2004 , 2006, British Journal of Cancer.

[252]  G. Vlastos,et al.  Complete excision of primary breast tumor improves survival of patients with metastatic breast cancer at diagnosis. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[253]  S. Bauer-Wu,et al.  Mindfulness Meditation for Oncology Patients: A Discussion and Critical Review , 2006, Integrative cancer therapies.

[254]  John R Yarnold,et al.  Effect of radiotherapy fraction size on tumour control in patients with early-stage breast cancer after local tumour excision: long-term results of a randomised trial. , 2006, The Lancet. Oncology.

[255]  G. Hortobagyi,et al.  Effect of Primary Tumor Extirpation in Breast Cancer Patients Who Present With Stage IV Disease and an Intact Primary Tumor , 2006, Annals of Surgical Oncology.

[256]  X. Shu,et al.  Association of ginseng use with survival and quality of life among breast cancer patients. , 2006, American journal of epidemiology.

[257]  J. Sloan,et al.  Phase III comparison of depomedroxyprogesterone acetate to venlafaxine for managing hot flashes: North Central Cancer Treatment Group Trial N99C7. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[258]  J. Manson,et al.  Low-fat dietary pattern and risk of colorectal cancer: the Women's Health Initiative Randomized Controlled Dietary Modification Trial. , 2006, JAMA.

[259]  M. Berger,et al.  Activity of the dual kinase inhibitor lapatinib (GW572016) against HER-2-overexpressing and trastuzumab-treated breast cancer cells. , 2006, Cancer research.

[260]  J. Richardson,et al.  Mindfulness-Based Stress Reduction as supportive therapy in cancer care: systematic review. , 2005, Journal of advanced nursing.

[261]  C. Owen,et al.  Breast-feeding and cancer: the Boyd Orr cohort and a systematic review with meta-analysis. , 2005, Journal of the National Cancer Institute.

[262]  J. Baselga,et al.  Maintaining normal hemoglobin levels with epoetin alfa in mainly nonanemic patients with metastatic breast cancer receiving first-line chemotherapy: a survival study. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[263]  P. Ganz,et al.  Outcomes from the Moving Beyond Cancer psychoeducational, randomized, controlled trial with breast cancer patients. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[264]  M. Pike,et al.  An overview of menopausal oestrogen–progestin hormone therapy and breast cancer risk , 2005, British Journal of Cancer.

[265]  Y Wang,et al.  Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials , 2005, The Lancet.

[266]  Thomas Helleday,et al.  Specific killing of BRCA2-deficient tumours with inhibitors of poly(ADP-ribose) polymerase , 2005, Nature.

[267]  Alan Ashworth,et al.  Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy , 2005, Nature.

[268]  Ramaswamy Nilakantan,et al.  Optimization of 6,7-disubstituted-4-(arylamino)quinoline-3-carbonitriles as orally active, irreversible inhibitors of human epidermal growth factor receptor-2 kinase activity. , 2005, Journal of medicinal chemistry.

[269]  E. Vittinghoff,et al.  Management of Postmenopausal Hot Flushes With Venlafaxine Hydrochloride: A Randomized, Controlled Trial , 2005, Obstetrics and gynecology.

[270]  L. Goldstein,et al.  Prognostic and predictive factors in early-stage breast cancer. , 2004, The oncologist.

[271]  M. Zenn,et al.  A Randomized Controlled Comparison of Electro-Acupoint Stimulation or Ondansetron Versus Placebo for the Prevention of Postoperative Nausea and Vomiting , 2004, Anesthesia and analgesia.

[272]  Alex Sparreboom,et al.  Herbal remedies in the United States: potential adverse interactions with anticancer agents. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[273]  K. Collins,et al.  Acupuncture and Acupressure for the Management of Chemotherapy‐Induced Nausea and Vomiting , 2004, Journal of the American Academy of Nurse Practitioners.

[274]  T. Reimer,et al.  Nutrition and Lifestyle Factors on the Risk of Developing Breast Cancer , 2003, Breast Cancer Research and Treatment.

[275]  J. Manson,et al.  A prospective study of oral contraceptive use and risk of breast cancer (Nurses' Health Study, United States) , 2004, Cancer Causes & Control.

[276]  P. Flynn,et al.  Differential effects of paroxetine on fatigue and depression: a randomized, double-blind trial from the University of Rochester Cancer Center Community Clinical Oncology Program. , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[277]  Hiram S. Cody,et al.  A Nomogram for Predicting the Likelihood of Additional Nodal Metastases in Breast Cancer Patients With a Positive Sentinel Node Biopsy , 2003, Annals of Surgical Oncology.

[278]  P. Johnston,et al.  BRCA1 functions as a differential modulator of chemotherapy-induced apoptosis. , 2003, Cancer research.

[279]  A. Ellis.  Breast , 2002, BMJ : British Medical Journal.

[280]  Valerie Beral,et al.  Breast cancer and hormone-replacement therapy in the Million Women Study , 2003, The Lancet.

[281]  K. Ditto.  SSRI discontinuation syndrome , 2003, Postgraduate medicine.

[282]  V. Dumeaux,et al.  Breast cancer and specific types of oral contraceptives: A large Norwegian cohort study , 2003, International journal of cancer.

[283]  Barbara L. Smith,et al.  Randomized trial of dose-dense versus conventionally scheduled and sequential versus concurrent combination chemotherapy as postoperative adjuvant treatment of node-positive primary breast cancer: first report of Intergroup Trial C9741/Cancer and Leukemia Group B Trial 9741. , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[284]  Youngjoo Lee,et al.  A ginsenoside-Rh1, a component of ginseng saponin, activates estrogen receptor in human breast carcinoma MCF-7 cells , 2003, The Journal of Steroid Biochemistry and Molecular Biology.

[285]  M. Stockler,et al.  Bisphosphonates for breast cancer. , 2005, The Cochrane database of systematic reviews.

[286]  M. Morrow,et al.  Does aggressive local therapy improve survival in metastatic breast cancer? , 2002, Surgery.

[287]  D. Keefe,et al.  Trastuzumab‐associated cardiotoxicity , 2002, Cancer.

[288]  J. Ranstam,et al.  Breast cancer and breastfeeding: collaborative reanalysis of individual data from 47 epidemiological studies in 30 countries, including 50 302 women with breast cancer and 96 973 women without the disease , 2002, The Lancet.

[289]  Oral contraceptives and the risk of breast cancer. , 2002, The New England journal of medicine.

[290]  P. Mellon,et al.  Estrogenic activity of herbs commonly used as remedies for menopausal symptoms , 2002, Menopause.

[291]  H. Adami,et al.  Use of oral contraceptives and breast cancer risk: The Norwegian-Swedish Women's Lifestyle and Health Cohort Study. , 2002, Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology.

[292]  Daniel J Buysse,et al.  Comparative meta-analysis of pharmacotherapy and behavior therapy for persistent insomnia. , 2002, The American journal of psychiatry.

[293]  R. Goldbohm,et al.  Familial breast cancer: collaborative reanalysis of individual data from 52 epidemiological studies including 58 209 women with breast cancer and 101 986 women without the disease , 2001, The Lancet.

[294]  M Metaxas,et al.  Targeted intra-operative radiotherapy (Targit): an innovative method of treatment for early breast cancer. , 2001, Annals of oncology : official journal of the European Society for Medical Oncology.

[295]  Debra L Barton,et al.  Venlafaxine in management of hot flashes in survivors of breast cancer: a randomised controlled trial , 2000, The Lancet.

[296]  E. Perez,et al.  Pilot evaluation of venlafaxine hydrochloride for the therapy of hot flashes in cancer survivors. , 1998, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[297]  P. Haddad.  The SSRI discontinuation syndrome , 1998, Journal of psychopharmacology.

[298]  D Machin,et al.  Radiotherapy with or without hyperthermia in the treatment of superficial localized breast cancer: results from five randomized controlled trials. International Collaborative Hyperthermia Group. , 1996, International journal of radiation oncology, biology, physics.

[299]  K. Folkers,et al.  Progress on therapy of breast cancer with vitamin Q10 and the regression of metastases. , 1995, Biochemical and biophysical research communications.

[300]  A. Howell,et al.  A randomised study to compare the effect of the luteinising hormone releasing hormone (LHRH) analogue goserelin with or without tamoxifen in pre- and perimenopausal patients with advanced breast cancer. , 1995, European journal of cancer.

[301]  K. Folkers,et al.  Partial and complete regression of breast cancer in patients in relation to dosage of coenzyme Q10. , 1994, Biochemical and biophysical research communications.

[302]  D. Krebs,et al.  [The effect of adjuvant combined chemo/immunotherapy on immunological parameters and clinical course in patients with breast carcinoma]. , 1991, Zentralblatt fur Gynakologie.

[303]  W. McGuire,et al.  Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. , 1987, Science.